Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 29, 2025
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …
UK regulated cloud mining: Earn Mining launches new short-term contracts and free mining opportunities
GlobeNewswire
·
May 29, 2025
Brisbane, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- As the best cloud mining platform in 2025, it does not require the purchase of expensive mining machines. Users can mine online without any equipment and obtain stable income. Cloud mining is becoming …
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
·
May 29, 2025
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at …
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
GlobeNewswire
·
May 29, 2025
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire
·
May 29, 2025
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies …
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
GlobeNewswire
·
May 29, 2025
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency
GlobeNewswire
·
May 29, 2025
REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay …
Lantronix to Showcase AI-Driven LM4 Out-of-Band Management Console Servers at Cisco Live San Diego
GlobeNewswire
·
May 29, 2025
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for IoT solutions enabling Edge AI Intelligence, today announced that it will do live demos and daily giveaways of its LM4 AI-driven …
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
GlobeNewswire
·
May 29, 2025
NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been …
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event …
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
GlobeNewswire
·
May 29, 2025
Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves’ disease (GD) and a potentially registrational study in Sjögren’s disease …
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
GlobeNewswire
·
May 29, 2025
Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: …
Azimut and KGHM Launch Exploration Campaign at Kukamas
GlobeNewswire
·
May 29, 2025
LONGUEUIL, Quebec, May 29, 2025 (GLOBE NEWSWIRE) -- Azimut Exploration Inc. (“Azimut” or the “Company”) (TSXV: AZM) (OTCQX: AZMTF) is pleased to announce that a comprehensive partner-funded exploration program is commencing on the Kukamas Property (the “ …
Azimut et KGHM débutent la campagne d’exploration sur Kukamas
GlobeNewswire
·
May 29, 2025
LONGUEUIL, Québec, 29 mai 2025 (GLOBE NEWSWIRE) -- Exploration Azimut Inc. (« Azimut » ou la « Société ») (TSXV: AZM) (OTCQX: AZMTF) annonce qu’un vaste programme d’exploration financé par le partenaire débute sur la Propriété Kukamas (la « Propriété ») …
SPEC Releases New SPECapc for SNX 2024 Benchmark
GlobeNewswire
·
May 29, 2025
GAINESVILLE, Va., May 29, 2025 (GLOBE NEWSWIRE) -- The Standard Performance Evaluation Corporation (SPEC), the trusted global leader in computing benchmarks, today announced the availability of an all-new SPECapc for SNX 2024 benchmark, providing a …
Integral Metals Announces Start of High-Resolution Soil Sampling Program at the KAP Project
GlobeNewswire
·
May 29, 2025
CALGARY, Alberta, May 29, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce that the Phase 2 soil sampling program has officially commenced at the Company’s 100%-owned …